血清CCL18与TM4SF1水平检测在卵巢良恶性肿瘤鉴别诊断中的价值研究  

Research on the Value of Detection of the Serum CCL18 and TM4SF1 Levels in Differential Diagnosis of Benign and Malignant Ovarian Tumors

作　　者：丁洁[1] 李阿利 李静[1] DING Jie;LI A-li;LI Jing(Department of Obstetrics and Gynecology,No.987 Hospital of the Joint Service Support Force of the People’s Liberation Army,Shaanxi Baoji 721000,China)

机构地区：[1]中国人民解放军联勤保障部队第九八七医院妇产科,陕西宝鸡721000

出　　处：《现代检验医学杂志》2021年第4期93-95,180,共4页Journal of Modern Laboratory Medicine

摘　　要：目的研究血清趋化因子配体18(chemokine ligand 18,CCL18)与四次跨膜蛋白1(transmembrane-4-L-sixfamily-member-1,TM4SF1)水平检测在卵巢良恶性肿瘤鉴别诊断中的应用价值。方法收集中国人民解放军联勤保障部队第九八七医院妇产科自2018年7月~2020年7月收治的84例卵巢肿瘤患者作为研究对象,患者均接受血清CCL18和TM4SF1检测。比较良性肿瘤与恶性肿瘤血清CCL18和TM4SF1水平,分析血清CCL18和TM4SF1鉴别良恶性卵巢肿瘤的价值。结果84例卵巢肿瘤患者中良性和恶性分别为48例和36例。良性肿瘤与恶性肿瘤患者血清CCL18,TM4SF1水平比较,差异均有统计学意义(t=9.05,6.42,均P<0.05)。受试者工作曲线(receiver operating characteristic,ROC)分析显示血清CCL18和血清TM4SF1联合预测概率判断卵巢恶性肿瘤的曲线下面积(area under curve,AUC)为0.85,显著高于血清CCL18和血清TM4SF1单项检测,差异有统计学意义(P<0.05)。结论血清CCL18和TM4SF1联合检测有助于鉴别卵巢良恶性肿瘤。Objective To study the application value of detection of the serum chemokine ligand 18(CCL18)and transmembrane-4-L-six-family-member-1(TM4SF1)in the differential diagnosis of benign and malignant ovarian tumors.Methods A total of 84 patients with ovarian tumor admitted to the Department of Obstetrics and Gynecology of No.987 Hospital of the Joint Logistic Support Force of the People’s Liberation Army from July 2018 to July 2020 were collected as the research subjects,all patients received serum CCL18 and TM4SF1 detection.The serum levels of CCL18 and TM4SF1 in benign and malignant tumors were compared,the value of serum CCL18 and TM4SF1 in differentiating benign and malignant ovarian tumors were analyzed.Results There were 48 cases of benign and 36 cases of malignant among 84 cases of ovarian tumor.There were significant differences in serum CCL18 and TM4SF1 levels between benign and malignant tumor patients(t=9.05,6.42,all P<0.05).The receiver operating characteristic(ROC)analysis showed that the area under curve(AUC)of joint prediction probability of serum CCL18 and TM4SF1 to diagnose the ovarian cancer was 0.85,which was higher than that of single test of serum CCL18 and TM4SF1 and the difference were statistically significant(P<0.05).Conclusion The combined detection of CCL18 and TM4SF1 is helpful to differentiate benign and malignant ovarian tumors.

关 键 词：卵巢良恶性肿瘤 血清趋化因子配体18 血清四次跨膜蛋白1 鉴别诊断 

分 类 号：R737.31[医药卫生—肿瘤] R730.43[医药卫生—临床医学]